Giá hiện tại
Giá mục tiêu
Đánh giá của nhà phân tích
1 xếp hạng: Mua
Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels wor...|
e.g. Promoter holding
Loading chart...
Dự báo EPS và doanh thu theo đồng thuận của các nhà phân tích.
| Metric (B) | FY 2027 | FY 2028 |
|---|---|---|
| — | — | |
| 0.03 | 0.09 | |
| — | — |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AAI Financi... | AIFC | $22.65M | — | 0.03 | — | -202.40% | -79.70% | -96.70% |
| 2. | BAllbirds I... | BIRD | $17.14M | — | 0.75 | -48.60% | -53.00% | -193.20% | -93.10% |
| 3. | DDarkHorse... | DRK | $16.09M | — | 1.01 | — | -143.80% | -140.20% | 15.60% |
| 4. | AauthID Inc | AUID | $2.88M | — | 1.54 | — | -962.00% | -414.00% | -66.00% |
| 5. | RRocket One | RKTO | $7.99M | — | 0.97 | — | — | -148.50% | — |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Quarter (M) | Dec 23 | Sep 24 | Dec 24 | Sep 25 |
|---|---|---|---|---|
Revenue | 5.91 | -5.89 | 0.06 | -0 |
COGS | 6.08 | -6.11 | 0.06 | 0.5 |
Gross Profit | -0.17 | 0.21 | -0.24 | -0.27 |
Gross Profit % | -2.84% | -3.58% | -376.19% | 13450% |
| 4.35 | 4.21 | 2.57 | 5.66 | |
EBIT | -4.52 | -4 | -2.59 | -6.15 |
OPM % | -76.45% | 67.88% | -4106.35% | 307600% |
Non-Operating Income | -3.21 | -32.19 | -3.2 | -3.2 |
PBT | -7.73 | -36.19 | -5.78 | -9.35 |
Income Tax | -0.2 | 1.8 | 0.38 | -1.07 |
Tax Rate % | 2.54% | -4.97% | -6.59% | 11.47% |
Net Income | -7.83 | -38.87 | -4.48 | -8.32 |
NPM % | -132.45% | 659.52% | -7104.76% | 415800% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|
Revenue | 23.98 | 10.16 | 4.05 | 0.02 | 0.06 | 2.54 |
COGS | 19.61 | 11.37 | 8.14 | -0.03 | 0.57 | 1.93 |
Gross Profit | 4.36 | -1.21 | -4.09 | 0.04 | -0.51 | 0.61 |
Gross Profit % | 18.19% | -11.91% | -100.84% | 268.75% | -829.51% | 24.01% |
| 29.76 | 25.01 | 15.83 | 8.62 | 8.23 | 25.95 | |
EBIT | -5.78 | -14.85 | -11.77 | -8.61 | -8.74 | -25.34 |
OPM % | -24.12% | -146.16% | -290.28% | -53800% | -14326.23% | -995.68% |
Non-Operating Income | -2.38 | -8.81 | -7.74 | -35.61 | -6.39 | -23.39 |
PBT | -8.16 | -23.66 | -19.51 | -44.22 | -15.13 | -48.73 |
Income Tax | 0 | 0 | 0 | 0 | -0.69 | 1.62 |
Tax Rate % | - | - | - | - | 4.57% | -3.32% |
Net Income | -7.57 | -22.05 | -24.36 | -46.7 | -12.79 | -49.73 |
NPM % | -31.58% | -217.07% | -600.62% | -291875% | -20970.49% | -1954.11% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|
| 8.6 | 1.28 | 0.55 | 0.2 | 0.25 | 2.02 | |
| 0 | 0 | 0.07 | 0 | 0 | 8.5 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 6.93 | 5.75 | 3.83 | 1.71 | 74.32 | 75.45 | |
| 60.98 | 62.62 | 56.97 | 35.52 | 22.56 | 70.46 | |
Total Assets | 76.51 | 69.66 | 61.42 | 37.43 | 97.13 | 156.43 |
| 0 | 0 | 0 | 0 | 2.7 | 3.69 | |
| 40.42 | 21.61 | 3.75 | -40.54 | 17.4 | 33.25 | |
| 21.85 | 26.1 | 30.08 | 29.09 | 29.19 | 39.03 | |
| 4.33 | 7.19 | 10.22 | 26.49 | 43.01 | 75.8 | |
| 9.91 | 14.76 | 17.36 | 22.4 | 4.83 | 4.66 | |
Total Liabilities | 76.51 | 69.66 | 61.42 | 37.43 | 97.13 | 156.43 |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|---|
| 0 | -15.38 | -5.13 | -5.44 | 1.49 | -5.75 | -3.59 | |
| 0 | 0 | 0 | 0 | 0 | -3.23 | -32.07 | |
| 0 | 23.54 | 3.56 | 6.69 | 2.72 | 8.84 | 37.62 | |
Net CFNet Cash Flow | 0 | 8.16 | -1.57 | 1.25 | 4.21 | -0.14 | 1.96 |
FCFFree Cash Flow | 0 | -16.31 | -10.55 | -10.33 | -3.1 | -6.73 | -4.41 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|
| - | -71.1% | -192.1% | 253.9% | 125.2% | -174.4% | |
| 0.53 | 0.99 | 7.52 | -0.52 | 1.45 | 1.06 | |
| 1.82 | 0.93 | 0.55 | 0.33 | 1.35 | 0.87 | |
| - | 0.14 | 0.06 | 0.00 | 0.00 | 0.02 | |
Cash Conversion | 2.03 | 0.23 | 0.22 | -0.03 | 0.45 | 0.07 |
Payout Ratio | - | - | - | - | - | - |
| - | -57.6% | -60.1% | -99.6% | 281.3% | 4072.1% | |
| - | - | - | - | - | - | |
| - | - | - | - | - | - | |
| 0.00 | 1.00 | 1.00 | 3.00 | 6.00 | 3.00 | |
| - | -3.88 | -4.50 | -60.50 | -0.32 | 13.44 | |
| 20.00 | 20.00 | 0.00 | 100.00 | 13.33 | 26.67 | |
| -0.3% | -2.2% | -6.0% | -2918.8% | -209.7% | -19.5% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Ai sở hữu Meridian Bioscience Inc, theo hồ sơ SEC
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| % of shares outstanding | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 9.17% | — | 3.25% | 3.25% | 3.25% | — | 15.68% | 14.66% | -1.02 | |
ForeignForeign institutions | 0.00% | — | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00 |
USUS institutions | 0.00% | — | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00 |
Govt.Government & pensions | 0.00% | — | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00 |
Public | 90.83% | — | 96.75% | 96.75% | 96.75% | — | 84.32% | 85.34% | +1.02 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Investment company | C0 | 6,500,000 | 23.60% | SC 13G · 18 May 2026 | |
| Investment company | C0 | 1,000,000 | 9.89% | SC 13G · 20 Aug 2025 | |
| Corporation | MO | 0 | 0.00% | SC 13G/A · 12 Feb 2026 | |
| Individual | — | 590,000 | 4.70% | SC 13G/A · 31 Oct 2025 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | % of shares out | Days to cover | Relative size |
|---|---|---|---|---|---|
| 30 Oct 2026 | 2,039,476 | -4.6% | 6.64% | 1.46 | |
| 15 Oct 2026 | 2,138,803 | -0.1% | 6.96% | 4.13 | |
| 30 Sep 2026 | 2,141,359 | +7.8% | 6.97% | 5.31 | |
| 15 Sep 2026 | 1,986,895 | -8.7% | 6.47% | 7.10 | |
| 31 Aug 2026 | 2,176,566 | +19.1% | 7.08% | 5.21 | |
| 14 Aug 2026 | 1,828,066 | -15.8% | 5.95% | 3.73 | |
| 31 Jul 2026 | 2,172,364 | -16.4% | 7.07% | 2.48 | |
| 15 Jul 2026 | 2,598,167 | +7.0% | 8.46% | 2.48 | |
| 30 Jun 2026 | 2,427,864 | -25.8% | 7.90% | 1.42 | |
| 15 Jun 2026 | 3,274,058 | -9.7% | 10.66% | 1.93 | |
| 29 May 2026 | 3,625,623 | +18.4% | 11.80% | 1.42 | |
| 15 May 2026 | 3,062,964 | +12.5% | 9.97% | 1.71 | |
| 30 Apr 2026 | 2,722,806 | +22.2% | 8.86% | 1.70 | |
| 15 Apr 2026 | 2,227,797 | +15.8% | 7.25% | 7.63 | |
| 31 Mar 2026 | 1,923,594 | -22.7% | 6.26% | 2.37 | |
| 31 Jan 2023 | 4,470,996 | +5.6% | 14.55% | 3.38 | |
| 13 Jan 2023 | 4,235,583 | +11.3% | 13.79% | 9.79 | |
| 30 Dec 2022 | 3,806,212 | +11.1% | 12.39% | 7.44 | |
| 15 Dec 2022 | 3,426,358 | +80.1% | 11.15% | 3.96 | |
| 30 Nov 2022 | 1,902,890 | -1.9% | 6.19% | 6.67 | |
| 15 Nov 2022 | 1,939,096 | -4.4% | 6.31% | 7.46 | |
| 31 Oct 2022 | 2,027,542 | -9.4% | 6.60% | 7.28 | |
| 14 Oct 2022 | 2,238,895 | +0.5% | 7.29% | 7.64 | |
| 30 Sep 2022 | 2,226,746 | -22.9% | 7.25% | 6.63 |
FINRA consolidated short interest, reported twice a month for every US listing.
Hồ sơ SEC và bản ghi cuộc gọi kết quả kinh doanh của Meridian Bioscience Inc
What recent news says about Meridian Bioscience Inc, scored for sentiment.